Baidu
map

Anesthesiology:围术期心肺骤停患者的转归分析

2014-06-24 佚名 大查房网

美国的一项研究表明,围术期心肺骤停患者的出院生存率为1/3,并且这些幸存者的神经功能全面恢复率为2/3。围术期心肺骤停类型和发生地点为患者生存预测因子。入院时神经功能状态、年龄、先天通气不足情况、通气支持情况、心肺骤停持续时间和地点均为出院时患者神经功能状态的显著预测因子。该研究结果于2013年12月发表在《麻醉学》(Anesthesiology)上。 围术期心肺骤停并不常见,其院内生存


美国的一项研究表明,围术期心肺骤停患者的出院生存率为1/3,并且这些幸存者的神经功能全面恢复率为2/3。围术期心肺骤停类型和发生地点为患者生存预测因子。入院时神经功能状态、年龄、先天通气不足情况、通气支持情况、心肺骤停持续时间和地点均为出院时患者神经功能状态的显著预测因子。该研究结果于2013年12月发表在《麻醉学》(Anesthesiology)上。

围术期心肺骤停并不常见,其院内生存率及生存预测因子尚不清楚。已有一些研究报道了围术期心肺骤停的发生率及发生风险因素,但是这些研究均为典型的单一机构、小样本研究(样本量最大的研究纳入223例患者),故研究结果不具有普遍性。该研究旨在,描述分析在手术室(OR)或术后24 h内出现心脏停搏患者的管理和预后。

该回顾性研究纳入在术中或术后24 h内,发生心肺骤停的患者,这些患者≥18岁。收集并分析这些患者的信息,如心肺骤停类型和发生地点、心肺骤停发生后存活时间、入院和出院时神经功能状态等信息。主要转归为出院生存率,次要转归为幸存患者的神经功能全面恢复率。

研究结果为,该研究共纳入234所医院的2524例围术期心肺骤停患者。1485例(58.7%)患者心肺骤停后恢复自主循环(ROSC),1151例(45.5%)心肺骤停后存活时间≥24 h,799例(31.7%)存活并出院。在799例存活并出院的患者中,无脉性室性心动过速(PVT)和心室颤动(VF)患者占41.8%(254/608),心脏停搏患者占30.5%(296/972),无脉性电活动(PEA)患者占26.4%(249/944)(表1)。PVT和VF均与生存率升高独立相关。大部分心脏停搏发生在手术室(OR)内(1458/2524)。在麻醉恢复室(PACU)发生心肺骤停患者的生存率最高(214/536,39.8%),余下依次为接受远程监测时发生心肺骤停的患者(20/58,35.1%),在OR内发生心肺骤停的患者(455/1458,31.2%),在普通病房内发生心肺骤停的患者(34/140,24.3%),在重症监护治疗病房(ICU)内发生心肺骤停的患者(76/332,23.0%)。心肺骤停发生在OR和PACU室内与生存率升高相关。1431例患者入院时脑功能分级(CPC)评分为1(2240例患者具有入院时CPC评分数据),其中566例患者存活并出院,445例(80%)患者出院时CPC评分仍为1。因此,入院时CPC评分为1的患者发生围术期心肺骤停后,31.1%的患者出院时神经功能完好。在出院时接受神经功能评估的患者中,64.0%(473/739)的患者神经功能全面恢复。入院时神经功能状态、年龄、先天通气不足情况、通气支持情况、心肺骤停持续时间和地点均为出院时患者神经功能状态的显著预测因子。


研究者认为,对于围术期心肺骤停患者,出院生存率为1/3,并且这些幸存者的神经功能完好恢复率为2/3。心肺骤停类型和发生地点为患者生存预测因子。入院时神经功能状态、年龄、先天通气不足情况、通气支持情况、心肺骤停持续时间和地点均为出院时患者神经功能状态的显著预测因子。对于麻醉医师,该研究结果可能具有指导意义。


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1684384, encodeId=1498168438450, content=<a href='/topic/show?id=dfae5133e1d' target=_blank style='color:#2F92EE;'>#心肺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51337, encryptionId=dfae5133e1d, topicName=心肺)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8e128082444, createdName=aids222, createdTime=Sun Apr 12 20:39:00 CST 2015, time=2015-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050408, encodeId=9726205040847, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Fri Jul 25 10:39:00 CST 2014, time=2014-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1275359, encodeId=730d12e53598a, content=<a href='/topic/show?id=6a39406551e' target=_blank style='color:#2F92EE;'>#围术期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40655, encryptionId=6a39406551e, topicName=围术期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5fca128, createdName=licz0423, createdTime=Thu Jun 26 07:39:00 CST 2014, time=2014-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1588160, encodeId=df3f1588160fc, content=<a href='/topic/show?id=1cb8e014e0' target=_blank style='color:#2F92EE;'>#ESI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7014, encryptionId=1cb8e014e0, topicName=ESI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4f817593223, createdName=skhzy, createdTime=Thu Jun 26 07:39:00 CST 2014, time=2014-06-26, status=1, ipAttribution=)]
    2015-04-12 aids222
  2. [GetPortalCommentsPageByObjectIdResponse(id=1684384, encodeId=1498168438450, content=<a href='/topic/show?id=dfae5133e1d' target=_blank style='color:#2F92EE;'>#心肺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51337, encryptionId=dfae5133e1d, topicName=心肺)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8e128082444, createdName=aids222, createdTime=Sun Apr 12 20:39:00 CST 2015, time=2015-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050408, encodeId=9726205040847, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Fri Jul 25 10:39:00 CST 2014, time=2014-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1275359, encodeId=730d12e53598a, content=<a href='/topic/show?id=6a39406551e' target=_blank style='color:#2F92EE;'>#围术期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40655, encryptionId=6a39406551e, topicName=围术期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5fca128, createdName=licz0423, createdTime=Thu Jun 26 07:39:00 CST 2014, time=2014-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1588160, encodeId=df3f1588160fc, content=<a href='/topic/show?id=1cb8e014e0' target=_blank style='color:#2F92EE;'>#ESI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7014, encryptionId=1cb8e014e0, topicName=ESI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4f817593223, createdName=skhzy, createdTime=Thu Jun 26 07:39:00 CST 2014, time=2014-06-26, status=1, ipAttribution=)]
    2014-07-25 xiangyuzhou971
  3. [GetPortalCommentsPageByObjectIdResponse(id=1684384, encodeId=1498168438450, content=<a href='/topic/show?id=dfae5133e1d' target=_blank style='color:#2F92EE;'>#心肺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51337, encryptionId=dfae5133e1d, topicName=心肺)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8e128082444, createdName=aids222, createdTime=Sun Apr 12 20:39:00 CST 2015, time=2015-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050408, encodeId=9726205040847, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Fri Jul 25 10:39:00 CST 2014, time=2014-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1275359, encodeId=730d12e53598a, content=<a href='/topic/show?id=6a39406551e' target=_blank style='color:#2F92EE;'>#围术期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40655, encryptionId=6a39406551e, topicName=围术期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5fca128, createdName=licz0423, createdTime=Thu Jun 26 07:39:00 CST 2014, time=2014-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1588160, encodeId=df3f1588160fc, content=<a href='/topic/show?id=1cb8e014e0' target=_blank style='color:#2F92EE;'>#ESI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7014, encryptionId=1cb8e014e0, topicName=ESI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4f817593223, createdName=skhzy, createdTime=Thu Jun 26 07:39:00 CST 2014, time=2014-06-26, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1684384, encodeId=1498168438450, content=<a href='/topic/show?id=dfae5133e1d' target=_blank style='color:#2F92EE;'>#心肺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51337, encryptionId=dfae5133e1d, topicName=心肺)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8e128082444, createdName=aids222, createdTime=Sun Apr 12 20:39:00 CST 2015, time=2015-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050408, encodeId=9726205040847, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Fri Jul 25 10:39:00 CST 2014, time=2014-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1275359, encodeId=730d12e53598a, content=<a href='/topic/show?id=6a39406551e' target=_blank style='color:#2F92EE;'>#围术期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40655, encryptionId=6a39406551e, topicName=围术期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5fca128, createdName=licz0423, createdTime=Thu Jun 26 07:39:00 CST 2014, time=2014-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1588160, encodeId=df3f1588160fc, content=<a href='/topic/show?id=1cb8e014e0' target=_blank style='color:#2F92EE;'>#ESI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7014, encryptionId=1cb8e014e0, topicName=ESI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4f817593223, createdName=skhzy, createdTime=Thu Jun 26 07:39:00 CST 2014, time=2014-06-26, status=1, ipAttribution=)]
    2014-06-26 skhzy

相关资讯

Eur Heart J:围术期新型口服抗凝药的应用策略

德国一项研究表明,对于大部分有创操作而言,持续应用或短期中断新型口服抗凝药(NOAC)治疗为一种安全策略。论文1月6日在线发表于《欧洲心脏杂志》(Eur Heart J)。 应用NOAC的患者较常接受手术操作治疗。此项前瞻性研究共纳入2179例应用NOAC的患者,并从中采集了有效性和安全性数据。利用标准事件定义对转归事件加以判定。 结果显示,595例(27.3%

NEJM:非心脏手术患者围术期用阿司匹林或可乐定不改善预后(POISE-2研究)

2014年美国心脏病学会年会(ACC 2014)公布的POISE-2研究表明,在接受非心脏手术的患者中,围术期应用阿司匹林或可乐定(clonidine)均不能减少患者死亡或心肌梗死发生率,应用阿司匹林还与额外严重出血显著相关,可乐定则与额外临床低血压、心动过缓和非致命性心搏骤停显著相关。大出血和低血压是术后心肌梗死的预测因子。研究3月31日在线发表于《新英格兰医学杂志。 研究纳入接受非心脏手

《围术期神经系统监测》出版中文版

由首都医科大学附属北京天坛医院麻醉科主任韩如泉教授和中国医师协会神经电生理监测委员会主任委员、北京市神经外科研究所神经电生理室主任乔慧研究员主译的《围术期神经系统监测》专著近日由北京大学医学出版社出版。 原版专著主编Antoun Koht、Tod B. Sloan教授欣然为中文版作序。该专著是神经生理监测领域非常重要的一部参考书,重点面向麻醉科医师、神经电生理医师及

Baidu
map
Baidu
map
Baidu
map